DEVELOPMENT OF ORAL FORM OF DTPA FOR USE IN RADIONUCLIDE DECORPORATION, 9/30/2013

用于放射性核素脱除的口服 DTPA 的开发，2013 年 9 月 30 日

• 批准号: 8752280
• 负责人: MICHAEL JAY
• 金额: $ 7.5万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8752280
• 关键词: Advanced Development; Calcium; Chelating Agents; Complex; Contracts; Development; Excision; Gastrointestinal tract structure; Investigational New Drug Application; Metabolic Clearance Rate; National Institute of Allergy and Infectious Disease; Nebulizer; Oral; Pentetic Acid; Plasma; Plutonium; Prodrugs; Radiation; Radioactive; Radioisotopes; Research Personnel; Staging; Zinc; diethylenetriaminepentaacetate

The removal of certain internal radioactive contaminants can be accomplished by administering chelating agents that can preferentially complex with radionuclides in the body and increase their rate of clearance, thereby decreasing radiation exposure. Pentetate (diethylenetriaminepentaacetate) calcium trisodium (Ca-DTPA) and pentetate (diethylenetriaminepentaacetate) zinc trisodium (Zn-DTPA) have been shown to be effective in treating internal contamination with radionuclides such as plutonium, americium, or curium. However, because DTPA must be given intravenously or by nebulizer, it is not useful in a mass casualty situation. This Contract advances the development of an oral form of DTPA that is more suitable for a mass casualty situation.

某些内部放射性污染物的清除可以通过给予螯合剂来完成，螯合剂可以优先与体内的放射性核素结合并增加其清除率，从而减少辐射照射。五酸（二乙烯三胺五乙酸酯）钙三钠（Ca-DTPA）和五酸（二乙烯三胺五乙酸酯）锌三钠（Zn-DTPA）已被证明对处理放射性核素如钚、镅或curium的内部污染有效。然而，由于DTPA必须通过静脉注射或雾化器给予，它在大规模伤亡的情况下是没有用的。该合同促进了口头形式的DTPA的发展，更适合大规模伤亡情况。